The cell and gene therapy market is rapidly expanding, with projections indicating growth from $14.2 billion in 2022 to $117.1 billion by 2032, at a compound annual growth rate (CAGR) of 24%. This growth is driven by an increase in clinical trials and a rising number of product approvals. Within this market, oncology remains the most active therapeutic segment throughout all stages of development.
Download a sample of this report @ https://www.towardshealthcare.com/personalized-scope/5052
Cell and gene therapies represent groundbreaking approaches within healthcare, utilizing living cells and genetic materials to treat various medical conditions. Cell therapy involves the administration of live cells to restore or enhance cellular function, while gene therapy introduces or modifies genetic material to correct genetic disorders or alter cellular behavior. These therapies are applicable to a broad range of diseases, including cancer, genetic disorders, cardiovascular diseases, neurodegenerative diseases, and autoimmune disorders, enhancing their market potential.
Oncology continues to be a major focus area in the development of cell and gene therapies. By 2021, more than 1,300 candidates were in development specifically for cancer treatment, underscoring the significant investment and research aimed at improving patient outcomes in this domain.
The biopharma sector is witnessing a surge in investments and innovation, with both large multinational companies and emerging startups investing heavily in advanced therapies. In 2018, investment in cell, gene, and gene-modifying treatments reached approximately $13 billion. By the following year, 19 significant mergers and acquisitions in the cell and gene therapy space totaled over $156 billion. Currently, over 900 companies worldwide are dedicated to these therapies, with more than 1,000 clinical trials underway. Starting in 2025, the industry anticipates 10 to 20 new advanced therapies receiving approval annually.
Europe is a key region for this growth, hosting 33% of the ongoing clinical trials. Advanced Therapeutic Medicinal Products (ATMPs) in Europe include CAR-T and TCR-T therapies, stem cells, siRNA, oligonucleotides, gene editing technologies like CRISPR, Zinc Fingers, and TALENs, and viral transfection methods.
Collaborations, acquisitions, and investments are crucial in advancing and commercializing cell and gene therapies. The complexity of these therapies necessitates multidisciplinary expertise and substantial financial resources. Strategic partnerships between pharmaceutical companies, biotech firms, academic institutions, and research organizations have become common, facilitating the development, manufacturing, and commercialization of innovative treatments.
Several notable acquisitions occurred in Q2 2021, such as Sanofi’s acquisition of Tidal Therapeutics for $470 million and Charles River Laboratories’ purchase of Vigene Biosciences for $350 million. These deals highlight the strategic importance of expanding capabilities and enhancing market positions within the cell and gene therapy sector.
Clinical trials are fundamental to the development and commercialization of cell and gene therapies. They assess the safety and efficacy of these innovative treatments, provide evidence for regulatory approvals, and establish their clinical value. Between 2020 and 2021, the number of therapies in preclinical development increased significantly from 911 to 1,223, indicating substantial growth in research and development.
As of May 2021, around 1,745 therapies were in various stages of development, from preclinical to preregistration. These trials are essential for evaluating safety, efficacy, and the economic value of these therapies, ultimately driving market growth by demonstrating their potential to address unmet medical needs.
North America leads the global cell and gene therapy market, driven by advanced healthcare infrastructure, a strong regulatory framework, and substantial investments in research and development. The prevalence of chronic diseases, such as cancer and genetic disorders, fuels demand for personalized and effective treatments, positioning North America as a hub for innovation.
The Asia Pacific region is emerging as a promising market due to its large population, rising prevalence of chronic diseases, and increased investments in healthcare infrastructure. Countries like Japan and China have implemented supportive regulatory frameworks and initiatives to accelerate the development of cell and gene therapies.
The cell and gene therapy market offers numerous opportunities, including addressing the growing prevalence of chronic diseases, expanding into new markets, and leveraging advances in gene editing technologies. However, the sector faces challenges such as high development costs, complex manufacturing processes, stringent regulatory requirements, and ethical concerns related to genetic modification.
Innovative therapies are central to the growth of the cell and gene therapy market, offering new solutions for patients with limited treatment options. The development of personalized therapies, advancements in gene editing technologies, and regulatory support are driving market expansion. With continued investment, collaboration, and innovation, the cell and gene therapy market is poised for significant growth, transforming the landscape of healthcare.
Major companies in the market include Alnylam Pharmaceuticals Inc., Amgen Inc., Biogen Inc., CORESTEM Inc., Dendreon Pharmaceuticals LLC., Helixmith Co. Ltd., JCR Pharmaceuticals Co. Ltd., Kolon TissueGene Inc., Novartis AG, and Pfizer Inc. These players are employing strategies like investments, alliances, acquisitions, and mergers to strengthen their market positions and foster growth.
By Therapy Type
By Therapeutic Class
By Delivery Method
By End-Users
By Region
Read Also: https://www.healthcarewebwire.com/precision-oncology-market/
Discover our detailed Table of Contents (TOC) for the Industry, providing a thorough examination of market segments, material, emerging technologies and key trends. Our TOC offers a structured analysis of market dynamics, emerging innovations, and regional dynamics to guide your strategic decisions in this rapidly evolving healthcare field – https://www.towardshealthcare.com/table-of-content/cell-and-gene-therapy-market
To own our research study instantly, Click here @ https://www.towardshealthcare.com/price/5052
You can place an order or ask any questions, please feel free to contact us at sales@towardshealthcare.com
About Us
Towards Healthcare is a leading global provider of technological solutions, clinical research services, and advanced analytics to the healthcare sector, committed to forming creative connections that result in actionable insights and creative innovations. We are a global strategy consulting firm that assists business leaders in gaining a competitive edge and accelerating growth. We are a provider of technological solutions, clinical research services, and advanced analytics to the healthcare sector, committed to forming creative connections that result in actionable insights and creative innovations.
Explore the comprehensive statistics and insights on healthcare industry data and its associated segmentation: Get a Subscription
For Latest Update Follow Us: https://www.linkedin.com/company/towards-healthcare
The rheumatoid arthritis drugs market size achieved a value of USD 17.87 billion in 2023 with this trajectory, it is… Read More
The ambulatory surgical centers market accounted for USD 94.57 billion in 2022 and is predicted to increase to USD 167.1… Read More
The global dental services market accounted for USD 432.1 billion in 2022 and is expected to hit US$ 699.7 billion… Read More
The cell and gene therapy manufacturing market size is estimated for US$ 3,755.4 million in 2022 to reach an estimate… Read More
The global CAR T-Cell therapy market is estimated to grow from USD 3.87 billion in 2022 at 29.8% CAGR (2023-2032)… Read More
Overview The automotive electronic stability control system market was valued at USD 40.65 billion in 2022 and is expected to… Read More